{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T23:38:27Z","timestamp":1789256307293,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006399","name":"Spectrum Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009269","name":"Amyloidosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jgo.2021.12.004","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T01:25:15Z","timestamp":1639704315000},"page":"486-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myeloma"],"prefix":"10.1016","volume":"13","author":[{"given":"Smith","family":"Giri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly N.","family":"Godby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Olszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Buford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jgo.2021.12.004_bb0005","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.jgo.2021.12.004_bb0010","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jgo.2021.12.004_bb0015","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2014-10-609461","article-title":"Future distribution of multiple myeloma in the United States by sex, age, and race\/ethnicity","volume":"125","author":"Rosenberg","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jgo.2021.12.004_bb0020","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2021.12.004_bb0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2012.067058","article-title":"Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials","volume":"98","author":"Palumbo","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jgo.2021.12.004_bb0030","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2009.07.006","article-title":"Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989","volume":"46","author":"Schaapveld","year":"2010","journal-title":"Eur J Cancer"},{"issue":"25","key":"10.1016\/j.jgo.2021.12.004_bb0035","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2021.12.004_bb0040","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S1470-2045(18)30348-6","article-title":"Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer","volume":"19","author":"Soto-Perez-de-Celis","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2021.12.004_bb0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.exger.2014.01.024","article-title":"The frailty syndrome: clinical measurements and basic underpinnings in humans and animals","volume":"54","author":"Mohler","year":"2014","journal-title":"Exp Gerontol"},{"issue":"3","key":"10.1016\/j.jgo.2021.12.004_bb0050","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"13","key":"10.1016\/j.jgo.2021.12.004_bb0055","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jgo.2021.12.004_bb0060","doi-asserted-by":"crossref","first-page":"894","DOI":"10.6004\/jnccn.2017.0122","article-title":"Frailty index developed from a cancer-specific geriatric assessment and the association with mortality among older adults with cancer","volume":"15","author":"Guerard","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"issue":"9","key":"10.1016\/j.jgo.2021.12.004_bb0065","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/cncr.21422","article-title":"Developing a cancer-specific geriatric assessment: a feasibility study","volume":"104","author":"Hurria","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jgo.2021.12.004_bb0070","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK myeloma research Alliance risk profile): a development and validation study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.jgo.2021.12.004_bb0075","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jgo.2021.12.004_bb0080","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jgo.2021.12.004_bb0085","unstructured":"Dale, W., et al., How is geriatric assessment used in clinical practice for older adults with cancer? A survey of cancer providers by the American Society of Clinical Oncology. JCO Oncol Pract p. OP.20.00442."},{"issue":"9","key":"10.1016\/j.jgo.2021.12.004_bb0090","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2217\/bmm-2016-0103","article-title":"A peripheral blood biomarker estimates probability of survival: the neutrophil-lymphocyte ratio in noncancer patients","volume":"10","author":"Davis","year":"2016","journal-title":"Biomark Med"},{"issue":"3","key":"10.1016\/j.jgo.2021.12.004_bb0095","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000490488","article-title":"The derived neutrophil-to-lymphocyte ratio is an independent prognostic factor in transplantation ineligible patients with multiple myeloma","volume":"140","author":"Lee","year":"2018","journal-title":"Acta Haematol"},{"issue":"6","key":"10.1016\/j.jgo.2021.12.004_bb0100","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.jgo.2021.12.004_bb0105","doi-asserted-by":"crossref","first-page":"650","DOI":"10.18632\/aging.101162","article-title":"Frailty and inflammatory markers in older adults with cancer","volume":"9","author":"Nishijima","year":"2017","journal-title":"Aging (Albany NY)"},{"issue":"3","key":"10.1016\/j.jgo.2021.12.004_bb0110","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative oncology group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2021.12.004_bb0115","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/s41375-021-01247-9","article-title":"External validation of the FIRST trial's simplified frailty score in a population-based cohort","volume":"35","author":"Mian","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jgo.2021.12.004_bb0120","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1111\/1475-6773.12872","article-title":"Development and validation of a high-quality composite real-world mortality endpoint","volume":"53","author":"Curtis","year":"2018","journal-title":"Health Serv Res"},{"issue":"49","key":"10.1016\/j.jgo.2021.12.004_bb0125","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/jncimonographs\/lgu020","article-title":"Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in surveillance, epidemiology, and end results (SEER) registries","volume":"2014","author":"Kish","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"1","key":"10.1016\/j.jgo.2021.12.004_bb0130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/sim.4780040112","article-title":"A Wilcoxon-type test for trend","volume":"4","author":"Cuzick","year":"1985","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.jgo.2021.12.004_bb0135","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jgo.2021.12.004_bb0140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1100\/tsw.2001.58","article-title":"Accumulation of deficits as a proxy measure of aging","volume":"1","author":"Mitnitski","year":"2001","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.jgo.2021.12.004_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arr.2016.08.006","article-title":"Inflammation and frailty in the elderly: a systematic review and meta-analysis","volume":"31","author":"Soysal","year":"2016","journal-title":"Ageing Res Rev"},{"issue":"5","key":"10.1016\/j.jgo.2021.12.004_bb0150","doi-asserted-by":"crossref","first-page":"319","DOI":"10.18632\/aging.100745","article-title":"Biological ageing and frailty markers in breast cancer patients","volume":"7","author":"Brouwers","year":"2015","journal-title":"Aging (Albany NY)"},{"issue":"6","key":"10.1016\/j.jgo.2021.12.004_bb0155","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.mad.2012.05.005","article-title":"Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85+ study","volume":"133","author":"Collerton","year":"2012","journal-title":"Mech Ageing Dev"},{"issue":"15_suppl","key":"10.1016\/j.jgo.2021.12.004_bb0160","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1200\/JCO.2021.39.15_suppl.6537","article-title":"Racial differences in geriatric assessment (GA) impairments, health-related quality of life (HRQOL), and body composition in older adults with gastrointestinal (GI) malignancies: results from the cancer and aging resilience evaluation (CARE) registry","volume":"39","author":"Williams","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2021.12.004_bb0165","doi-asserted-by":"crossref","first-page":"13538","DOI":"10.1038\/s41598-020-70470-8","article-title":"Examining multimorbidity differences across racial groups: a network analysis of electronic medical records","volume":"10","author":"Kalgotra","year":"2020","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.jgo.2021.12.004_bb0170","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3109\/10428194.2014.982642","article-title":"Neutrophil to lymphocyte ratio improves prognostic prediction of international prognostic index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone","volume":"56","author":"Keam","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.jgo.2021.12.004_bb0175","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1309\/AJCPO46GFKGNXCBR","article-title":"Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma","volume":"138","author":"Koh","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.jgo.2021.12.004_bb0180","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00277-013-1978-8","article-title":"Predicting survival for multiple myeloma patients using baseline neutrophil\/lymphocyte ratio","volume":"93","author":"Kelkitli","year":"2014","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.jgo.2021.12.004_bb0185","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00277-015-2462-4","article-title":"Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents","volume":"94","author":"Romano","year":"2015","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.jgo.2021.12.004_bb0190","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1054\/bjoc.2001.2162","article-title":"Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer","volume":"85","author":"Ando","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jgo.2021.12.004_bb0195","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3332\/ecancer.2019.913","article-title":"How do clinicians rate patient's performance status using the ECOG performance scale? A mixed-methods exploration of variability in decision-making in oncology","volume":"13","author":"Datta","year":"2019","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"10.1016\/j.jgo.2021.12.004_bb0200","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187940682100268X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187940682100268X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:56:07Z","timestamp":1761818167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187940682100268X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S187940682100268X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2021.12.004","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2021.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}